Immunic Therapeutics says it's "on track" in its MS clinical trials of vidofludimus calcium, with CALLIPER top-line data ...

Columnist Ben Hofmeister explains a handy acronym that's helped him and can help you motivate yourself with MS.

Men with MS who started on high-efficacy DMTs had fewer relapses than those who started with moderate-efficacy DMTs, a U.S.

MS patients show large differences between vascular age and chronological age, even if they don't have cardiovascular disease ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

Columnist Ahna Crum is taking on a new year with a different approach: meeting the day-to-day new beginnings in life with ...

Scientists say IRX4204 given to mice with evident symptoms showed potential "as a remyelinating and neurorestorative ...

Long-term Tecfidera use was found to significantly reduce relapse rates and slow disability progression for MS patients in a ...

Most MS treatments don't increase the risk for miscarriage or major birth defects when used during pregnancy, an analysis ...

Certain health issues seen in youth with MS in the five years before diagnosis confirm a prodromal period may exist in ...

The most-read stories published by Multiple Sclerosis News Today in 2024 focused on living with MS and news on disease risk factors.

Columnist Ben Hofmeister is learning that navigating life with multiple sclerosis is a journey, rather than a quest or an adventure.